COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.77M | 1.48M | 2.75M | 1.50M | 3.32M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.77M | 1.48M | 2.75M | 1.50M | 3.32M |
| Cost of Revenue | 1.16M | 938.00K | 1.78M | 1.06M | 1.27M |
| Gross Profit | 609.00K | 545.00K | 974.00K | 443.00K | 2.05M |
| SG&A Expenses | 2.40M | 2.10M | 2.64M | 2.93M | -1.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.15M | 3.57M | 5.10M | 5.12M | 2.85M |
| Operating Income | -2.39M | -2.08M | -2.35M | -3.62M | 471.00K |
| Income Before Tax | -2.17M | -1.82M | -2.70M | -3.66M | -5.65M |
| Income Tax Expenses | 10.00K | -- | 1.00K | -- | 1.08M |
| Earnings from Continuing Operations | -2.18M | -1.82M | -2.70M | -3.66M | -6.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.18M | -1.82M | -2.70M | -3.66M | -6.73M |
| EBIT | -2.39M | -2.08M | -2.35M | -3.62M | 471.00K |
| EBITDA | -4.46M | -1.80M | -2.07M | -3.29M | 520.00K |
| EPS Basic | -1.37 | -0.57 | -0.85 | -1.16 | -2.14 |
| Normalized Basic EPS | -0.85 | -0.31 | -0.53 | -0.73 | 0.24 |
| EPS Diluted | -1.37 | -0.57 | -0.85 | -1.16 | -2.14 |
| Normalized Diluted EPS | -0.85 | -0.31 | -0.53 | -0.73 | 0.24 |
| Average Basic Shares Outstanding | 6.38M | 3.18M | 3.17M | 3.14M | 3.14M |
| Average Diluted Shares Outstanding | 6.38M | 3.18M | 3.17M | 3.14M | 3.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |